Northland Capmk Weighs in on BLFS Q4 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk issued their Q4 2025 earnings per share (EPS) estimates for BioLife Solutions in a research note issued on Wednesday, January 8th. Northland Capmk analyst C. Byrnes anticipates that the medical equipment provider will post earnings of $0.00 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ FY2026 earnings at $0.10 EPS.

A number of other brokerages have also recently weighed in on BLFS. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. TD Cowen increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Craig Hallum upped their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Price Performance

BLFS opened at $27.69 on Friday. The company has a fifty day moving average price of $25.99 and a two-hundred day moving average price of $24.29. BioLife Solutions has a 52 week low of $14.50 and a 52 week high of $28.88. The firm has a market capitalization of $1.28 billion, a PE ratio of -26.12 and a beta of 1.92. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC bought a new position in BioLife Solutions in the 3rd quarter valued at about $57,000. GAMMA Investing LLC raised its position in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $122,000. Finally, Summit Global Investments acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $228,000. 93.24% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. The trade was a 0.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 113,129 shares of company stock valued at $2,576,818 over the last 90 days. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.